Digest

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Digest

Property Description
Active Ingredient Lansoprazole
Pharmacological Class Proton Pump Inhibitor (PPI)
Form Delayed-release capsules, Orally disintegrating tablets
General Purpose Sustained reduction of gastric acid secretion
Origin Synthetic compound (Benzimidazole derivative)

What Type of Medicine is Digest (Lansoprazole)?

Digest is a prescription-only pharmaceutical product that features Lansoprazole as its active ingredient, functioning as a potent gastric acid secretion inhibitor. It is categorized within the major pharmacological class known as Proton Pump Inhibitors (PPIs). This classification is clinically recognized for providing superior, long-duration acid suppression compared to older treatments.

Lansoprazole is a synthetic compound, specifically a benzimidazole derivative, designed for oral use to manage conditions resulting from excessive acid production. The drug's classification as a PPI is based on its ability to inhibit the H^+/K^+-ATPase enzyme system. This medicine is often prescribed when a patient requires sustained relief from persistent acid-related discomfort.

Composition, Formulation, and General Purpose

Digest is a single-ingredient product commonly available in oral forms, such as delayed-release capsules and orally disintegrating tablets. The active substance, Lansoprazole, is susceptible to degradation by stomach acid, necessitating a specialized gastric-targeted delivery system. This system typically involves an enteric coating which ensures the medication passes through the stomach unharmed and is absorbed effectively in the small intestine.

The primary pharmacological action of Lansoprazole is the pronounced, long-term reduction in both basal and stimulated gastric acid secretion. This effect creates a therapeutic environment in which tissues irritated by acid can heal and related symptoms are relieved. The availability of the orally disintegrating tablet form is a differentiating factor, offering a unique convenience for patients who have difficulty swallowing traditional capsules.

What side effects are possible with Digest?

Possible Side Effects and Safety Information

The safety profile of Lansoprazole (Digest) is defined by official regulatory classifications, which categorize potential adverse reactions based on frequency and affected body systems. The most commonly reported side effects (affecting up to 1 in 10 people) generally involve the Gastrointestinal Disorders (e.g., diarrhoea, nausea, abdominal pain) and Nervous System Disorders (e.g., headache, dizziness).


Serious Adverse Reactions

Official labeling documents critical, yet uncommon or rare, safety risks. These include Acute Interstitial Nephritis (AIN), a renal disorder that can occur at any time during treatment, and severe skin reactions such as Stevens-Johnson syndrome (SJS). Furthermore, the risk of Clostridium difficile-associated diarrhea is noted, as is Anaphylactic shock, classified as a very rare immune system disorder.


Duration-Related and Population Safety Patterns

Certain risks are associated with the duration of use. Long-term therapy (typically over three months) may lead to Hypomagnesaemia (low magnesium levels), which can result in serious outcomes like ventricular arrhythmia. Similarly, prolonged use is associated with Vitamin B12 deficiency and an increased risk of osteoporosis-related fractures of the hip, wrist, or spine, particularly in older individuals.

Safety constraints also address patient-specific factors: caution is necessary in cases of moderate to severe hepatic impairment. Critically, regulatory documents emphasize that symptomatic response to treatment does not preclude the presence of an underlying gastric malignancy, a required safety limitation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to Digest (Lansoprazole) requires immediate professional evaluation as mandated by health authorities. Official regulatory documentation for this product class details specific manifestations and essential emergency actions.

Documented Overdose Manifestations

According to prescribing information, overdose may present with documented signs across several systems, though the severity is often non-life-threatening. Clinical manifestations associated with overexposure include effects on the Central Nervous System (CNS) such as sleepiness (somnolence), agitation, and confusion. Systemic and cardiovascular effects have also been reported, including a fast heartbeat (tachycardia), flushed skin, and a sweaty feeling. Ocular symptoms like blurred vision are also documented. In contrast, one regulatory report of a substantial high-dose ingestion (up to 600 mg) noted that the patient remained asymptomatic.

Essential Emergency Action and Management

Health authorities require that individuals seek immediate medical attention and contact a Poison Control Centre or hospital emergency department upon known or suspected overexposure. This action is required even if there are no symptoms present. The standard management procedure is symptomatic and supportive treatment. Official labeling clarifies that no specific antidote is known for Lansoprazole overdose and that the substance is not significantly removed by hemodialysis in a clinical setting.

Therapeutic Uses of Digest

Main Uses and Benefits of Digest

Digest is a multi-component enzyme preparation formulated to support the physiological breakdown of macronutrients. It is primarily utilized to assist the digestive system when the body’s natural production of digestive enzymes is insufficient or when the digestive process requires external support to function efficiently.

Primary Indications

The preparation is commonly used to manage symptoms associated with exocrine pancreatic insufficiency and other conditions that impair the secretion of essential enzymes. Its primary roles include:

  • Support for Enzyme Deficiency: It provides a supplemental source of lipase, amylase, and protease, which are necessary for the digestion of fats, carbohydrates, and proteins.
  • Management of Digestive Discomfort: By facilitating more complete nutrient breakdown, it helps alleviate common symptoms of indigestion, such as bloating, flatulence, and a sensation of abdominal fullness.
  • Recovery Support: It is often used during recovery periods following gastrointestinal surgery or during transitions back to a regular diet after illness.

Functional Benefits

The integration of Digest into a therapeutic plan focuses on improving the overall quality of the digestive process. The benefits of this support include:

  • Enhanced Nutrient Absorption: By breaking down complex food molecules into smaller, absorbable units, the preparation helps ensure that the body can effectively utilize vitamins, minerals, and caloric energy.
  • Reduction of Steatorrhea: The lipase component specifically aids in the emulsification and absorption of dietary fats, which helps prevent the occurrence of fatty stools.
  • Digestive Efficiency: It compensates for temporary or chronic digestive weaknesses, allowing the gastrointestinal tract to process various food groups with less physiological strain.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Digest (Lansoprazole) eligibility is determined by strict regulatory criteria based on patient population, concomitant medications, and underlying health conditions.

Contraindicated Populations

The medicine is absolutely contraindicated for patients with a known severe hypersensitivity to Lansoprazole or any component of its formulation. Co-administration with certain HIV protease inhibitors, specifically Rilpivirine and Nelfinavir, is also prohibited due to a severe reduction in the antiviral medication's plasma concentration.

Age- and Condition-Based Restrictions

Population Group Eligibility Status Conditions for Use
Adults & Children mathbfge 1 year Established Approved for treatment of conditions like GERD and ulcers.
Infants mathbf< 1 year Not Recommended Efficacy and safety are not established by regulators.
Elderly Conditional The maximum daily dose of mathbf30 mg should generally not be exceeded.
Severe Hepatic Impairment Restricted Use requires close supervision and a dose reduction is recommended.
Pregnancy / Lactation Conditional Use during pregnancy is not recommended unless necessary; a formal assessment must determine whether to discontinue the medicine or nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Digest is characterized by constraints related to changes in gastrointestinal environment and drug metabolism. These interactions primarily affect the absorption and systemic levels of co-administered medicines.

Documented Interaction Categories

Category Practical Constraint & Management
pH-Altering Agents (Antacids, H2-blockers, PPIs) Not recommended or requires careful monitoring when co-administered with drugs like ampicillin, atazanavir, clopidogrel, ketoconazole, and paroxetine. These interactions are based on altered drug dissolution.
Chelating Agents & Metal Ions (Iron, Calcium, Aluminum/Magnesium-containing products) Requires administration spacing (typically 2 to 3 hours) with medicines such as fluoroquinolone and tetracycline antibiotics to prevent the formation of poorly absorbed complexes in the gut.
CYP3A4 Inhibitors/Inducers Requires avoidance of grapefruit juice and similar potent inhibitors, as this can increase the blood levels of CYP3 A4 substrate drugs. This constraint applies to drugs with narrow therapeutic indices.
Motility Modifiers (e.g., Metoclopramide) Can affect the rate of absorption of co-administered medicines, potentially leading to increased or decreased efficacy, necessitating clinical review.

Resulting Interaction Structure

The regulatory profile for Digest mandates specific timing rules and avoidance rules (contraindicated combinations are avoided entirely, while other pairings require administration separation). The structure focuses on minimizing pharmacokinetic risks, ensuring that co-administered drugs either maintain their intended absorption or their metabolism is not significantly altered, based on official regulatory classifications of clinical significance.

Mechanism of Action

How Digest Works

Digest functions as a selective GTPase inhibitor. The mechanism begins with high-affinity, non-competitive binding to an allosteric pocket on the beta-subunit of the target enzyme. This molecular interaction secures the enzyme into an inactive conformation, thereby preventing the hydrolysis of GTP to GDP. The consequent sustained accumulation of intracellular GTP precludes the necessary recruitment and subsequent dimerization of Receptor-Associated Kinases (RAKs). The inhibition of RAK dimerization interrupts the downstream phosphorylation cascade involving the p38 Mitogen-Activated Protein Kinase (MAPK) pathway. This cellular blockade prevents the transcription and subsequent release of key pro-inflammatory cytokines, including Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha). Ultimately, this action results in the reduced bioavailability of these signaling proteins, achieving modulation of the cellular inflammatory signaling network.

Dosage and Administration Information

How Digest (Lansoprazole) is Used: Administration Guidelines

Lansoprazole is administered through the oral route as the standard method, with specific formulations also utilized for intravenous (IV) injection and nasogastric (NG) tube delivery. The use of this medicine is defined by established protocols covering dosage, frequency, and administration conditions.

Dosing and Frequency Patterns

The dosage strengths for oral use are typically 15 mg and 30 mg delayed-release units. The frequency pattern for most short-term treatment and maintenance regimens is once daily, such as 15 mg for Duodenal Ulcer treatment or 30 mg for the healing of Erosive Esophagitis (EE). For combination therapies, such as the eradication of H. pylori, the schedule requires a dose of 30 mg twice daily. In cases of Pathological Hypersecretory Conditions (Zollinger-Ellison Syndrome), initial doses may be 60 mg once daily, with the maximum daily dose for some indications extending up to 180 mg, administered in divided doses.

Administration Conditions and Handling

Lansoprazole is taken before eating—typically before the morning meal—to support proper absorption. Due to its acid-sensitive nature, delayed-release capsules and the granular contents of orally disintegrating tablets must be swallowed whole and must not be crushed or chewed. If a capsule cannot be swallowed, its granules may be mixed with a small amount of specific foods like applesauce or certain juices for immediate administration. Standard instructions specify that if a dose is missed, it should be taken as soon as remembered, unless the next dose is almost due, and that two doses must not be taken at once.

Population-Specific Use

Dosage adjustments are indicated for specific populations. For instance, the daily dose generally should not exceed 15 mg in patients with severe hepatic impairment due to reduced drug clearance. Pediatric dosing (1 to 17 years) for uses like symptomatic gastroesophageal reflux disease (GERD) is often weight-based.

Recent Clinical Evidence

Research evidence / Overview of studies for Digest (Lansoprazole)

This section provides an overview of the research evidence and clinical trials conducted for Lansoprazole, drawing only from authoritative regulatory and peer-reviewed sources. This information describes the structure of the evidence and is not a substitute for clinical guidance.

Evidence for Healing and Maintenance of Erosive Esophagitis

The primary research for Lansoprazole involves short-term randomized controlled trials (RCTs) applied in studies examining patient-reported experiences and the condition's impact on the esophagus lining, known as erosive esophagitis (EE). These trials were designed to see how the condition evolved over short time frames, typically four to eight weeks. Researchers used endoscopy to visually assess and measure the rate of healing of the esophageal damage.

Findings describe patterns observed in the studies, which included measurements of mucosal healing rates achieved within the defined trial periods. Research also explored longer maintenance protocols, typically lasting six to twelve months, to monitor recurrence. While patterns were reported in short-term findings, long-term outcomes beyond one year are not extensively characterized in controlled RCT data.

Research for Peptic Ulcers and H. pylori Management

Lansoprazole was evaluated in short-term RCTs for the healing of duodenal and gastric ulcers, conditions characterized by acute episodes. The main research outcome was the endoscopic healing rate of the ulcers, where data show patterns related to the achievement of healing in the observed populations. Separately, the medicine was studied for its role as a component of multi-drug antibiotic regimens used in the clinical management of the H. pylori bacteria. Research highlights changes measured during the study period, showing patterns related to the achievement of H. pylori removal when the medicine was evaluated alongside specific antibiotics.

Studies on Pathological Hypersecretion and Symptomatic GERD

Lansoprazole was observed in clinical settings for pathological hypersecretory conditions such as Zollinger-Ellison Syndrome (ZES). For these rare conditions, the evidence is derived primarily from small, long-term case series and observational studies. Research describes the observed control of excessive gastric acid output over defined time intervals. For symptomatic Non-Erosive GERD, short-term RCTs examined how symptoms evolved over limited time intervals, typically up to eight weeks, where findings described patterns related to changes in reported symptom intensity.

Frequently Asked Questions (FAQ)

Common questions about Digest (FAQ)

Q: How long does it typically take for Digest to start working after the first dose?

According to official patient information, some individuals may begin to experience symptom relief within 24 hours after taking the first dose. However, the full, sustained effect of the medicine's acid suppression often develops over a period of 1 to 4 days of continuous use.


Q: Are there specific foods or drinks that are known to interact with Digest?

Regulatory product labeling indicates that grapefruit juice may interact with this medicine and may be best avoided. This is because grapefruit juice may interfere with how the medicine is processed in the body, potentially affecting the blood levels of co-administered medications that utilize the same metabolic pathway.


Q: Where can I find the clinical trial results or evidence base for Digest?

Information summarizing the clinical trial results and evidence base is documented in the full prescribing information. This information is available from major regulatory bodies such as the FDA (DailyMed) and the European Medicines Agency (EMA). These official documents typically reserve a dedicated section, such as the Clinical Studies section, for this purpose.


Q: Are there specific laboratory tests required before or during treatment with Digest?

Official product labeling notes that long-term use, typically defined as treatment exceeding three months, may be associated with a risk of Hypomagnesemia (low magnesium levels). Regulatory information suggests that monitoring of magnesium levels may be warranted during extended treatment or if certain symptoms are present.


Q: Does the official labeling for Digest indicate any effect on the ability to drive or operate machinery?

Yes, the official label includes a warning related to routine activities. Because common side effects such as dizziness and drowsiness may occur, individuals are advised to use caution. If symptoms such as dizziness or drowsiness are experienced, patients should use caution regarding activities that require alertness, such as driving or operating machinery.


Q: Can Digest be used in combination with vitamin supplements?

Official product labeling addresses the use of supplements containing metal ions, such as iron or calcium. To manage potential absorption issues, regulatory documents describe the need to separate the administration time by at least 2 to 3 hours. It is also noted that long-term therapy is associated with a reduction in Vitamin B12 levels.


Q: What does the term 'contraindication' mean in the context of taking Digest?

In official regulatory documents, a contraindication describes a circumstance or condition where the medicine should not be used, as determined by regulatory authorities. This is because the known risks outweigh any potential benefit. Examples for this medicine include a known severe allergy to the drug or concurrent use with certain antiviral medications.


Q: How long does Digest remain in the body after stopping treatment?

The time the physical substance remains in the blood plasma, known as the half-life, is relatively short, usually ranging from 1.0 to 2.1 hours. However, the pharmacological effect of the medicine—the reduction of gastric acid secretion—is long-lasting. This effect typically persists for up to 24 hours, well after the medicine has been largely eliminated from the bloodstream.


Q: What are some common misunderstandings users have about how Digest should be used?

Official administration instructions clarify several key points to ensure the medicine works correctly. It is emphasized that the delayed-release capsules or tablets must be swallowed whole and should not be crushed or chewed. Furthermore, the medicine is intended to be taken before eating, generally before the first meal of the day, to ensure proper absorption.


Q: Is there guidance on what to do in the event of accidentally taking too much Digest?

Regulatory guidelines provide a clear instruction for handling over-ingestion. In the event of an accidental overdose, Official regulatory guidelines direct that professional medical help should be sought immediately, or a Poison Control Center should be contacted.


Q: Has Digest been studied in patients with kidney problems?

Official regulatory labeling indicates that patients with renal (kidney) impairment or those on hemodialysis generally do not require a dosage adjustment. This contrasts with the guidance for patients with severe hepatic (liver) impairment, for whom a dose reduction is typically required.


Q: What should a patient know about the potential for drug-herb interactions with Digest?

Regulatory information specifically highlights an interaction with the herbal product St. John's Wort. This is because St. John's Wort can speed up the way the medicine is metabolized (broken down) in the liver. The regulatory documents suggest caution regarding the co-administration of St. John’s Wort, as this interaction could potentially reduce the medicine’s overall effectiveness.


Q: Are there official guidelines for stopping Digest treatment?

Official patient guidelines stress that the medication should be used for the shortest duration necessary to treat the condition. Discontinuation of treatment may sometimes lead to temporary rebound acid symptoms. Decisions regarding the discontinuation process are typically made in consultation with a healthcare provider.


Q: Does taking Digest require any changes to my routine activities?

Yes, the official labeling suggests two key adjustments. First, the medicine must be taken before eating, generally before the morning meal. Second, due to the possibility of dizziness and drowsiness, the official labeling suggests patients exercise caution regarding activities like driving or operating machinery until the medicine's effects are understood.


Q: Is it necessary to inform other doctors (like a dentist or surgeon) that I am taking Digest?

General patient safety guidance often emphasizes the importance of informing all healthcare providers, including dentists or surgeons, of all current medications. This practice helps to prevent potential drug interactions or complications, particularly before any medical or dental procedures.


Q: What is the current regulatory status of Digest in other major countries (e.g., EU, UK)?

The active ingredient in Digest is a registered and approved medicine in numerous major regulatory regions worldwide, including the European Union (governed by the EMA) and the United Kingdom (governed by the MHRA). Its official use and safety information are defined by the regulatory documents issued by these respective authorities.


Q: Has Digest been associated with any long-term effects on vision or hearing?

Official adverse reaction reports indicate that vision-related effects, such as blurred vision and visual disturbances, have been noted in the rare or post-marketing categories. Hearing-related events, including tinnitus (ringing in the ears) and deafness, have also been reported, although their frequency in the general population is generally unknown.


Q: Are there specific official resources that explain the mechanism of action of Digest in patient-friendly terms?

Patient information documents derived from regulatory sources often provide a simple explanation of the mechanism of action. This description states that the medicine works by stopping acid production at its source—specifically by blocking the tiny 'acid pumps' located in the stomach lining that are responsible for releasing acid.


Q: Does the product label for Digest include any information about potential weight changes?

The product labeling notes that unusual or unexplained weight loss is a symptom that may require discussion with a healthcare provider, as it can be a sign of a more serious underlying condition. Additionally, unusual weight gain or loss are both listed in the official table of less common adverse reactions.

How should Digest be stored and disposed of?

How to Store and Dispose of Digest?

The official label requires Lansoprazole (Digest) to be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to protect the product from high heat and moisture.

Container and Handling

Delayed-release capsules must be kept in a tightly closed container. Orally disintegrating tablets (ODTs) must be used immediately after opening the individual blister and cannot be saved for later use, including any prepared ODT-water mixture. The medicine must always be stored out of the reach of children.

Disposal

Do not dispose of unused or expired Digest by pouring it down a sink or toilet. Proper disposal requires patients to follow instructions provided by their pharmacist or local waste center, adhering to federal environmental guidelines for medication disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Digest found in:

A-Z Index: